Research Funding Opportunities
We want to help kidney cancer researchers locate funding opportunities. We’ll update this page with grant opportunities as we learn about them.
Know of one we haven’t listed? Email us at info@kidneycan.org, or tweet at us, and we’ll get it posted!
KidneyCAN is dedicated to accelerating kidney cancer research.
Our advocacy for the DoD Kidney Cancer Research Program resulted in appropriations of $50 million in fiscal year 2023 for kidney cancer research, bring the 2017-2023 total to $235 million. In 2016, this number was $0.
The Kidney Cancer Research Summit brings translational researchers in kidney cancer together in an annual collaborative meeting.
Additionally, KidneyCAN’s “Rock the Cure” events have raised over $1,000,000 toward private research support.
KCRP FY23 FUNDING OPPORTUNITIES RELEASED
DUE JULY-SEPTEMBER
- Academy of Kidney Cancer Scholars – Early-Career Scholar Award
- Clinical Trial Award
- Concept Award
- Idea Development Award (New for FY23: Partnering Principal Investigator Option)
- Nurse-Initiated Research Award
- Postdoctoral and Clinical Fellowship Award
- Translational Research Partnership Award
ARPA-H supports high-impact biomedical research for equitable health solutions. Their model empowers program managers to tackle problems by working with a range of performers and approaches, and emphasizing measurement and evaluation for real-world impact.
The Advanced Research Projects Agency for Health (ARPA-H) seeks proposals for high-impact biomedical and health research to tackle society’s most challenging health problems, including cancer. The agency will fund groundbreaking, innovative research that can rapidly achieve better health outcomes across patient populations, communities, diseases, and health conditions.
Proposals must use novel approaches to enable revolutionary advances in science, technology, or systems. ARPA-H has identified four initial focus areas:
-
- Health Science Futures
- Scalable Solutions
- Proactive Health
- Resilient Systems
ARPA-H may consider submissions outside of these areas if they develop novel capabilities to improve health outcomes or prolong well-being. The agency will fund efforts across the spectrum of technology readiness, from foundational science to introducing new prototypes into the marketplace.
FUNDING OPPORTUNITY ANNOUNCEMENT
ARPA-H FREQUENTLY ASKED QUESTIONS
“ARPA-H will support concepts brought to life directly from Program Managers that have not only identified a key problem in health today, but are also passionate about a vision to bring forward revolutionary solutions to solve the problem, and do so in an equitable way.
“ARPA-H embraces a culture of open innovation and empowers its Program Managers to fearlessly pursue health breakthroughs that cannot readily be accomplished through traditional research or commercial activity. Program Managers at ARPA-H will serve an initial appointment of three years, and no more than six years total, to ensure a constant rotation of new ideas and diverse perspectives.”
Since 1993, the American Association for Cancer research has awarded more than $540 million in funds toward almost 1,000 different grants. In 2021, the AACR awarded over $7 million.
The ACCR supports grantees from the United States and abroad, at every career stage. These grants accelerate cancer research.
We’d love to see more RCC applicants for these prestigious grant opportunities.
KCRS is a meeting of clinicians, researchers, research advocates, scientists, medical oncologists, industry and others to discuss the future efforts for collaboration in the field of kidney cancer research.
Kidney cancer is the ideal sandbox for these new approaches, and without a doubt the same approach can, should and will be suitable for other cancers.
Dr. Hans Hammers, UTSW
RESEARCH UPDATES
From the Heart to the Hill: Advocating for Kidney Cancer Research Funding
Spring Advocacy : By the Numbers KidneyCAN is thrilled to announce the success of our Spring Advocacy Days event, which took place on March 13th in person in Washington, D.C., and on March 14th virtually. We are grateful for the 186 confirmed meetings with...
Lenny and Phyllis: “We Need to Keep Up the Fight”
Phyllis was diagnosed with kidney cancer in 2012. Tumors were found on both kidneys and treated with surgery. Her cancer progessed to stage IV in 2014, but Phyllis says, "Here I am, ten years later! Life has changed, but it is good!" For this month's Community...
The 2022 Kidney Cancer Research Summit
Dr. Laurence Albiges (Institut Gustave Roussy) presents on the microbiome at KCRS22. The microbiome has now been recognized as one of the emerging hallmarks and enabling characteristics of cancer. KidneyCAN hosted the 4th Annual Kidney Cancer Research Summit on...
Join Our Grassroots Army
;
📣 June 15 is #WorldKidneyCancerDay!
Join us with our partners @IKCCorg for a symposium on living well with #kidneycancer.
Register: https://www.worldkidneycancerday.org/register/
More resources at KidneyCAN's Patient Resource Center: https://bit.ly/LivingWellRCC
#WKCD2023 World Kidney Cancer Day Global Patient & Caregiver Symposium, please join us Thursday, June 15, to hear patients, caregivers and experts share their experiences and insights about living with #kidneycancer. See our website to register : https://worldkidneycancerday.org/register/
Updated results from ASCO ;the phase 2 CLEAR study (NCT02811861) show that the combination of lenvatinib/pembrolizumab sustained benefits in overall survival (OS) and progression-free survival for #KIDNEYCANCER patients
via @targetedonc
Kicking off the kidney cancer session the one and only @DrChoueiri with the results of the CONTACT-3 trial showing no significant benefit of adding Atezolizumab to cabozanitonib after prior ICI.
@ASCO #ASCO23
This negative trial addresses an important question that may have… https://twitter.com/i/web/status/1665761396540203009
About to kick off at #ASCO23
Genitourinary Cancer—Kidney and Bladder
Headlining: Our amazing @OncoAlert Faculty @DrChoueiri of @DanaFarberNews
11:30 – 14:30 GMT-5 • Hall D1
@DrYukselUrun @montypal @TiansterZhang @tompowles1 @HHammersMD @neerajaiims @apolo_andrea… https://twitter.com/i/web/status/1665757783969366016
And thanks to @BraunMDPhD for a truly terrific presentation! He recently started at @YaleCancer after working w @DrChoueiri & others at @DanaFarber, but demonstrates the expertise of someone who has been working in the field of #kidneycancer for years!
Flawless presentation by @DrChoueiri at #ASCO23 of #CONTACT03 results. We didn’t sleep much over the past several weeks putting this manuscript together for simultaneous pub in @TheLancet! Thank you to @katy_beckermann & @brian_rini for a terrific editorial accompanying the… https://twitter.com/i/web/status/1665765806389575681
1/ Results from #CONTACT03 are out both @ASCO #ASCO23 and @TheLancet . The 1⃣st phase 3 trial to assess the efficacy of rechallenge with anti-PDL1 in ANY cancer type.
Kudos to @montypal, SC members, @roche, our patients, = for this phenomenal job.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00922-4/fulltext
#ASCO23 @ASCO @brian_rini presents the long term follow up of KN-426 trial with pembrolizumab + axitinib in 1st line mRCC #kidneycancer 👉After a 67 month, robust benefit present after a long term followup.👇Congrats to all. @OncoAlert @KidneyCancer @kidneycan @Uromigos
Brilliant presentation by @EbrahimiHedyeh at #ASCO23 regarding the role of CBM588 with Nivo/Cabo in patients with mRCC. This, in conjunction with @NazliDizman presentation last year, is really paving the way we will be treating patients with mRCC in the not-so-far future
#ASCO23 @Chrislabaki1 sitting with giants, always making us extremely proud and soon heading to @BIDMC_IM residency!
A much needed analysis on outcomes for pts w/ sarcomatoid/rhabdoid #RCC under #IO
@ASCO @OncoAlert
Your favorite pathologists @Nourhanelahmar @SayedMatar12 presenting their work on biomarkers of response to Nivo in pts with #mRCC
#HCRN
#ASCO23
@ASCO @OncoAlert
The inimitable @BradMcG04 presenting the exciting results of “Can I?”. He surely can!
More data on IO+TKI efficacy in variant histology RCC, almost across the board.
Still a lot to do but builds beautifully on his prior work with AtezoBev in the same population of patients!… https://twitter.com/i/web/status/1665055420933713924
Lucky to be learning from a wonderful clincian and researcher @BradMcG04
He's currently tackling an unmet need
#CaNI testing Cabo/Nivo/Ipi in pts with #RCC with variant histology
#ASCO23
Super mentor @BraunMDPhD presenting the huge effort to understand the determinants of response to Nivo in #RCC through genomic and transcriptomic analyses
#ASCO23
Learning from the best at #ASCO23! @BradMcG04 discusses his research with @motzermd
